Maravai Lifesciences Sees Composite Rating Move Up To 96

The IBD SmartSelect Composite Rating for Maravai Lifesciences (MRVI) increased from 92 to 96 Thursday.


The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.

Maravai Lifesciences stock is trading about 3% above a 45.89 entry from a cup without handle. Keep in mind that it has fallen back to that buy area. It is currently below the moving averages and is fighting to regain support. More for a watch list than a buy list.

Looking For The Best Stocks To Buy And Watch? Start Here


One weak spot is the company’s 65 EPS Rating, which tracks quarterly and annual earnings-per-share growth. Look for that to improve to 80 or better to show it’s in the top 20% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks, including three  Mutual Funds from the IBD Fund Index.

The company reported 4,300% earnings-per-share growth for Q2. Sales growth increased 364%, up from 191% in the prior report. That marks four consecutive reports with increasing revenue gains.

Maravai Lifesciences stock earns the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Biontech Se Ads (BNTX) is the top-ranked stock within the group.


Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders


Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button